Narcolepsy – Executive Insights – Executive Insights (US)


The narcolepsy market has been characterized by a lack of available and on-label therapies as well as low diagnosis rates because patients often do not seek treatment; however, the market appears poised for expansion over the next ten years. The few available on-label therapies are considered to have high abuse potential, presenting obstacles for prescription as well as administration. Emerging agents are likely to expand treatment options. Some early-phase drugs offer a novel mode of administration or mechanism of action. Furthermore, at least one therapy in development (pitolisant) is not expected to be listed as a controlled substance, which is likely to reduce physician and patient concerns around prescribing, allowing for higher treatment rates. With a combined early- and late-phase development pipeline extending through at least 2027, DRG forecasts strong growth in the narcolepsy market over the next ten years.


  • What are the key areas of unmet need and opportunity in the narcolepsy market?
  • What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?
  •  How does each current and future player influence the market and how will this change in the future? ·
  • What are the key drivers and limiters of the narcolepsy market?


United States Primary Research 3 KOL interviews in November 2018


Jazz Pharmaceuticals, Teva, Harmony Biosciences

Key Drugs Covered

Xyrem, Nuvigil, Provigil, pitolisant, solriamfetol


Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

launch Related Market Assessment Reports